Repositioning Candidate Details
| Candidate ID: | R0207 |
| Source ID: | DB00595 |
| Source Type: | approved; investigational; vet_approved |
| Compound Type: | small molecule |
| Compound Name: | Oxytetracycline |
| Synonyms: | 5-Hydroxytetracycline; Embryostat; Hydroxytetracyclinum; Mepatar; Oxyterracin; Oxyterracine; Oxytetracycline; Oxytetracycline (anhydrous); Oxytetracycline amphoteric |
| Molecular Formula: | C22H24N2O9 |
| SMILES: | [H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(C=CC=C4O)[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C |
| Structure: |
|
| DrugBank Description: | A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions. |
| CAS Number: | 79-57-2 |
| Molecular Weight: | 460.434 |
| DrugBank Indication: | Oxytetracycline is indicated for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including <i>Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae</i> (respiratory infections), and <i>Diplococcus pneumoniae</i>. |
| DrugBank Pharmacology: | Oxytetracycline is known as a broad-spectrum antibiotic due to its activity against such a wide range of infections. It was the second of the tetracyclines to be discovered. Oxytetracycline, like other tetracyclines, is used to treat many infections common and rare. Its better absorption profile makes it preferable to tetracycline for moderately severe acne, but alternatives sould be sought if no improvement occurs by 3 months. |
| DrugBank MoA: | Oxytetracycline inhibits cell growth by inhibiting translation. It binds to the 30S ribosomal subunit and prevents the amino-acyl tRNA from binding to the A site of the ribosome. The binding is reversible in nature. Oxytetracycline is lipophilic and can easily pass through the cell membrane or passively diffuses through porin channels in the bacterial membrane. |
| Targets: | 30S ribosomal protein S9 inhibitor; 30S ribosomal protein S4 inhibitor; 16S ribosomal RNA inhibitor |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I01 | 552 | Pneumonia | A lung disease that involves lung parenchyma or alveolar inflammation and abnormal alveolar filling with fluid (consolidation and exudation). It results from a variety of causes including infection with bacteria, viruses, fungi or parasites, and chemical or physical injury to the lungs. It is accompanied by fever, chills, cough, and difficulty in breathing. http://en.wikipedia.org/wiki/Pneumonia | disease of anatomical entity/respiratory system disease/ lower respiratory tract disease/lung disease | Details |